Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 10

1.
2.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
3.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
4.
5.

Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

Molyneux PD, Filippi M, Barkhof F, Gasperini C, Yousry TA, Truyen L, Lai HM, Rocca MA, Moseley IF, Miller DH.

Ann Neurol. 1998 Mar;43(3):332-9. Review.

PMID:
9506550
6.

[Cladribin. Development of an oral formulation for the treatment of multiple sclerosis].

Hartung HP, Kieseier BC, Aktas O.

Nervenarzt. 2010 Feb;81(2):194-202. doi: 10.1007/s00115-009-2878-y. Review. German.

PMID:
20127230
7.

Development of oral cladribine for the treatment of multiple sclerosis.

Hartung HP, Aktas O, Kieseier B, Giancarlo Comi GC.

J Neurol. 2010 Feb;257(2):163-70. doi: 10.1007/s00415-009-5359-0. Review.

PMID:
19921304
8.

Cladribine tablets: in relapsing-remitting multiple sclerosis.

Muir VJ, Plosker GL.

CNS Drugs. 2011 Mar;25(3):239-49. doi: 10.2165/11204740-000000000-00000. Review.

PMID:
21323395
9.

Cladribine: mode of action and implications for treatment of multiple sclerosis.

Leist TP, Weissert R.

Clin Neuropharmacol. 2011 Jan-Feb;34(1):28-35. doi: 10.1097/WNF.0b013e318204cd90. Review.

PMID:
21242742
10.

[Treatment of multiple sclerosis with cladribine (2-CDA), a new immunosuppressant agent. Theoretical basis and preliminary results].

Grieb P, Stelmasiak Z.

Neurol Neurochir Pol. 1995 Jan-Feb;29(1):69-76. Review. Polish.

PMID:
7596480
Items per page

Supplemental Content

Write to the Help Desk